FDA approves Stelara for children aged 2 years and older with ulcerative colitis

The FDA has approved Stelara injection for the treatment of moderately to severely active ulcerative colitis in children aged 2 years and older, expanding the drug’s use for both major forms of pediatric IBD.The decision follows the FDA’s approval of Stelara (ustekinumab, Janssen) in April for children aged 2 years and older with Crohn’s disease. Ustekinumab is the first